Financial Data and Key Metrics Changes - Revenue for Q2 2025 was approximately $2.9 million, a 100% increase year over year and a slight sequential increase [5][17] - Gross margins improved to 43.6%, more than double the 20.3% reported in Q2 2024, and increased from 42.4% sequentially [5][18] - Adjusted EBITDA loss narrowed to negative $420,000 compared to negative $790,000 for the same period last year [6][20] - Net loss attributable to stockholders was $670,000, down from $890,000 in Q2 2024 [20] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased to $863,000, a 103% year over year increase from approximately $425,000 in 2024 [6] - Consumer products revenue increased by 95% year over year, driven by growth across the brand portfolio [12] Market Data and Key Metrics Changes - The company is seeing increased demand from domestic companies due to tariffs, although the impact on margins has been mild [35][36] - The partnership with Cintas remains strong, with ongoing sales of the SilverSeal product included in their wound care kits [7][75] Company Strategy and Development Direction - The company aims to continue expanding its contract manufacturing and white label business as a major driver of growth [11] - New product launches are planned, including an expanded beauty line and additional skincare solutions, reflecting the commitment to innovative, high-quality products [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive EBITDA by the end of the year and maintaining guidance for $13 million in revenue [15][81] - The company is preparing for potential economic downturns by focusing on high-margin consumer products and evaluating cost structures [66] Other Important Information - The company received $1 million in non-dilutive funding from STATA to support upcoming product launches and marketing initiatives [15][21] - The company has sufficient cash on hand, including recent capital raises, to support growth initiatives [21] Q&A Session Summary Question: Market opportunities for upcoming launches - Management discussed the potential for new digestive enzyme products, which target larger markets compared to existing products [22][23] Question: Retail strategy and brand consolidation - Management clarified that brands will maintain their unique identities and are currently exploring private label opportunities [25][27] Question: Manufacturing capacity and onboarding new customers - Current manufacturing capacity is underutilized, allowing for onboarding of new customers without immediate expansion [29][30] Question: Impact of tariffs on the business - Management noted a mild negative impact on margins but increased interest from domestic companies [35][36] Question: Status of AbbVie partnership - Management confirmed delays in the AbbVie project but remains optimistic about future developments [40][44] Question: New product details from Silly George - Management highlighted successful new product launches and strong sales performance [48][51] Question: Cash position and recession preparedness - Management is considering strategies for potential economic downturns while maintaining a focus on high-margin products [66] Question: Ranking of partnerships - Management identified key partnerships, including Cintas and AbbVie, as significant opportunities for growth [75]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-41173 NexGel, Inc. (Exact name of registrant as specified in its charter) | Delaware | 26-4042544 | | -- ...

Executive Summary & Highlights [Second Quarter 2025 Financial Highlights](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) NEXGEL achieved strong financial performance in Q2 2025, with revenue growing 100.3% YoY and gross margin significantly improving to 43.6%, while the adjusted EBITDA loss continued to narrow **Key Financial Metrics Comparison for Q2 2025 (in millions USD):** | Metric | Q2 2025 | Q2 2024 | YoY Change | Q1 2025 | QoQ Change | | :----- | :------ | :------ | :--------- | :------ | :--------- | | Net Revenue | $2.88 | $1.44 | +100.3% | $2.81 | +2.5% | | Gross Profit | $1.26 | $0.29 | +334.5% | $1.19 | +5.9% | | Gross Profit Margin | 43.6% | 20.3% | +23.3 pp | 42.4% | +1.2 pp | | Net Loss Attributable to NEXGEL Stockholders | ($0.67) | ($0.89) | -24.6% | ($0.71) | -5.6% | | EBITDA | ($0.53) | ($0.76) | -30.2% | ($0.58) | -8.6% | | Adjusted EBITDA | ($0.42) | ($0.79) | -46.8% | ($0.50) | -16.0% | [CEO Commentary and Outlook](index=1&type=section&id=CEO%20Commentary%20and%20Outlook) CEO Adam Levy highlighted strong Q2 2025 revenue and gross margin performance, reaffirming the full-year $13 million revenue guidance and the goal of achieving positive EBITDA - Year-over-year growth was primarily driven by increased consumer demand for branded products and new contract manufacturing agreements[4](index=4&type=chunk) - Subsequent to the quarter, the company expanded its partnership with STADA, including a **$1 million non-dilutive capital advance** to support product launch and marketing efforts[4](index=4&type=chunk)[11](index=11&type=chunk) - The company completed a **gross financing of $1.05 million**, sufficient to support upcoming growth initiatives[4](index=4&type=chunk)[11](index=11&type=chunk) - Reaffirmed the **2025 revenue guidance of $13 million** and plans to achieve **positive EBITDA** within the year[2](index=2&type=chunk)[4](index=4&type=chunk) Second Quarter 2025 Financial Results Analysis [Revenue and Cost of Revenues](index=1&type=section&id=Revenue%20and%20Cost%20of%20Revenues) Net revenues reached $2.88 million in Q2 2025, a 100.3% YoY increase, driven by growth in contract manufacturing and branded product sales, with a corresponding rise in cost of revenues **Revenue and Cost of Revenues (in millions USD):** | Metric | Q2 2025 | Q2 2024 | YoY Change | | :----- | :------ | :------ | :--------- | | Revenues, net | $2.88 | $1.44 | +100.3% | | Cost of revenues | $1.63 | $1.15 | +41.7% | - The increase in total revenues was primarily attributable to growth in contract manufacturing and branded product sales[5](index=5&type=chunk) - The increase in cost of revenues was primarily consistent with the growth in branded consumer product sales, as Silly George was acquired mid-way through the comparable period in 2024[6](index=6&type=chunk) [Gross Profit](index=1&type=section&id=Gross%20Profit) Gross profit for Q2 2025 substantially increased to $1.26 million with the gross margin improving to 43.6% from 20.3% in the prior year period **Gross Profit and Gross Margin (in millions USD):** | Metric | Q2 2025 | Q2 2024 | YoY Change | | :----- | :------ | :------ | :--------- | | Gross profit | $1.26 | $0.29 | +334.5% | | Gross profit margin | 43.6% | 20.3% | +23.3 pp | - The increase in gross profit was primarily due to growth in contract manufacturing and consumer branded product sales, along with the acquisition of Silly George mid-way through the comparable period in 2024[7](index=7&type=chunk) [Operating Expenses (Selling, General and Administrative)](index=1&type=section&id=Operating%20Expenses%20(Selling%2C%20General%20and%20Administrative)) Selling, general and administrative expenses for Q2 2025 rose to $1.89 million, primarily due to increased costs in compensation, stock-based compensation, and professional fees **Selling, General and Administrative Expenses (in millions USD):** | Metric | Q2 2025 | Q2 2024 | YoY Change | | :----- | :------ | :------ | :--------- | | Selling, general and administrative expenses | $1.89 | $1.27 | +48.8% | - The increase in expenses was attributable to rises in compensation and benefits, stock-based compensation, advertising, professional consulting fees, other expenses, and investor and stockholder services, partially offset by a decrease in depreciation and amortization[8](index=8&type=chunk) [Net Loss and Profitability Metrics](index=1&type=section&id=Net%20Loss%20and%20Profitability%20Metrics) NEXGEL reduced its net loss attributable to stockholders to $0.67 million in Q2 2025, with significant improvements in both EBITDA and Adjusted EBITDA **Net Loss and Profitability Metrics (in millions USD):** | Metric | Q2 2025 | Q2 2024 | YoY Change | | :----- | :------ | :------ | :--------- | | Net loss attributable to NEXGEL stockholders | ($0.67) | ($0.89) | -24.6% | | EBITDA | ($0.53) | ($0.76) | -30.2% | | Adjusted EBITDA | ($0.42) | ($0.79) | -46.8% | Financial Position and Liquidity [Cash and Financing Activities](index=2&type=section&id=Cash%20and%20Financing%20Activities) As of June 30, 2025, NEXGEL held a cash balance of approximately $0.73 million and secured additional funding post-quarter through a partnership expansion and financing **Cash Balance (in millions USD):** | Metric | As of June 30, 2025 | | :----- | :------------------ | | Cash Balance | $0.73 | - Expanded partnership with STADA, including a **$1 million non-dilutive capital advance** to support product launch and marketing efforts[4](index=4&type=chunk)[11](index=11&type=chunk) - Completed a **gross financing of $1.05 million**, sufficient to support upcoming growth initiatives[4](index=4&type=chunk)[11](index=11&type=chunk) [Condensed Consolidated Balance Sheets Overview](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets%20Overview) As of June 30, 2025, the company's total assets were $9.71 million, with total liabilities and stockholders' equity at $4.66 million and $5.06 million, respectively **Key Data from Condensed Consolidated Balance Sheets (in thousands USD):** | Metric | June 30, 2025 | December 31, 2024 | Change | | :----- | :------------ | :---------------- | :----- | | Total assets | $9,711 | $10,983 | ($1,272) | | Total liabilities | $4,656 | $4,903 | ($247) | | Total stockholders' equity | $5,055 | $6,080 | ($1,025) | | Cash | $725 | $1,807 | ($1,082) | | Total current assets | $4,162 | $5,114 | ($952) | | Total current liabilities | $2,396 | $2,470 | ($74) | Company Information & Disclosures [About NEXGEL, INC.](index=2&type=section&id=About%20NEXGEL%2C%20INC.) NEXGEL, Inc. is a leading provider of healthcare, beauty, and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogels - NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products, including ultra-gentle, high-water-content hydrogel products[14](index=14&type=chunk) - The company has over two decades of experience in electron-beam cross-linked hydrogel development and manufacturing in Langhorne, Pennsylvania[14](index=14&type=chunk) - NEXGEL's brands include SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George, and it maintains strategic contract manufacturing relationships with leading consumer healthcare companies[14](index=14&type=chunk) [Non-GAAP Financial Measures](index=2&type=section&id=Non-GAAP%20Financial%20Measures) The company utilizes non-GAAP financial measures like EBITDA and Adjusted EBITDA to provide a clearer view of its core operational performance for investors and management - Non-GAAP financial measures are intended to provide a representation of the company's core operating performance and information that may be useful in assessing its future prospects and potential trends[15](index=15&type=chunk) - Excluded items include amortization of intangible assets, stock-based compensation, adjusted tax impacts, other non-recurring items, and discrete items that impact the income tax provision[15](index=15&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) This section contains cautionary notes regarding forward-looking statements, which involve risks and uncertainties that could cause actual results to differ materially from expectations - Statements include expectations for significant growth opportunities in the second half of 2025, and continued expectations of at least **$13 million in revenue** and achieving **positive EBITDA** in 2025[16](index=16&type=chunk) - These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the company's actual results, performance, or achievements to be materially different from expectations[16](index=16&type=chunk) - The company does not intend and does not assume any obligation to revise any forward-looking statements[16](index=16&type=chunk) [Investor Relations](index=3&type=section&id=Investor%20Relations) This section provides contact information for investor inquiries, directed to Valter Pinto, Managing Director at KCSA Strategic Communications - Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications, Phone: 212.896.1254, Email: Nexgel@kcsa.com[18](index=18&type=chunk) Condensed Consolidated Financial Statements [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The condensed consolidated balance sheets present NEXGEL's financial position as of June 30, 2025, and December 31, 2024 **NEXGEL, INC. Condensed Consolidated Balance Sheets (in thousands USD):** | ASSETS: | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :---------------- | | Current Assets: | | | | Cash | $725 | $1,807 | | Accounts receivable, net | 753 | 933 | | Inventory, net | 1,821 | 1,751 | | Prepaid expenses and other current assets | 863 | 623 | | **Total current assets** | **4,162** | **5,114** | | Goodwill | 1,128 | 1,128 | | Intangibles, net | 744 | 807 | | Property and equipment, net | 2,070 | 2,211 | | Operating lease - right of use asset | 1,512 | 1,628 | | Other assets | 95 | 95 | | **Total assets** | **$9,711** | **$10,983** | | LIABILITIES AND STOCKHOLDERS' EQUITY | | | | Current Liabilities: | | | | Accounts payable | $826 | $761 | | Accounts payable - related party | 447 | 531 | | Accrued expenses and other current liabilities | 534 | 310 | | Deferred revenue | 180 | 179 | | Current portion of note payable | 99 | 97 | | Warrant liability | 14 | 118 | | Contingent consideration liability | - | 178 | | Financing lease liability, current portion | 62 | 59 | | Operating lease liabilities, current portion | 234 | 237 | | **Total current liabilities** | **2,396** | **2,470** | | Operating lease liabilities, net of current portion | 1,446 | 1,538 | | Financing lease liability, net of current portion | 275 | 307 | | Notes payable, net of current portion | 539 | 588 | | **Total liabilities** | **4,656** | **4,903** | | Stockholders' Equity: | | | | Common stock | 8 | 8 | | Additional paid-in capital | 24,036 | 23,743 | | Accumulated deficit | (19,373) | (17,996) | | Total NexGel stockholders' equity | 4,671 | 5,755 | | Non-controlling interest in joint venture | 384 | 325 | | **Total stockholders' equity** | **5,055** | **6,080** | | **Total liabilities and stockholders' equity** | **$9,711** | **$10,983** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The condensed consolidated statements of operations detail revenues, costs, expenses, and net loss for the three and six-month periods ending June 30, 2025 and 2024 **NEXGEL, INC. Condensed Consolidated Statements of Operations (in thousands USD):** | | Three Months Ended June 30, | | Six Months Ended June 30, | | | :------------------------------------------ | :------------ | :------------ | :------------ | :------------ | | | **2025** | **2024** | **2025** | **2024** | | Revenues, net | $2,884 | $1,440 | $5,690 | $2,706 | | Cost of revenues | 1,626 | 1,147 | 3,244 | 2,187 | | **Gross profit** | **1,258** | **293** | **2,446** | **519** | | Operating expenses: | | | | | | Research and development | - | 76 | 1 | 78 | | Selling, general and administrative | 1,894 | 1,271 | 3,858 | 2,366 | | **Total operating expenses** | **1,894** | **1,347** | **3,859** | **2,444** | | **Loss from operations** | **(636)** | **(1,054)** | **(1,413)** | **(1,925)** | | Other income (expense): | | | | | | Interest expense, net | (21) | (29) | (42) | (44) | | Loss on sale of assets | - | (4) | - | (4) | | Other expense | (37) | - | (76) | - | | Other income | 41 | 6 | 109 | 6 | | Gain on investments | - | 23 | - | 57 | | Changes in fair value of warrant liability | 13 | 79 | 104 | 26 | | **Total other income (expense), net** | **(4)** | **75** | **95** | **41** | | **Loss before income taxes** | **(640)** | **(979)** | **(1,318)** | **(1,884)** | | Income tax expense | - | - | - | - | | **Net loss** | **(640)** | **(979)** | **(1,318)** | **(1,884)** | | Less: Income (loss) attributable to non-controlling interest in joint venture | (25) | 94 | (59) | 146 | | **Net loss attributable to NexGel stockholders** | **$(665)** | **$(885)** | **$(1,377)** | **$(1,738)** | | Net loss per common share - basic | $(0.09) | $(0.14) | $(0.18) | $(0.28) | | Net loss per common share - diluted | $(0.09) | $(0.14) | $(0.18) | $(0.28) | | Weighted average shares used in computing net loss per common share - basic | 7,654,348 | 6,254,659 | 7,649,878 | 6,118,212 | | Weighted average shares used in computing net loss per common share – diluted | 7,654,348 | 6,254,659 | 7,649,878 | 6,118,212 | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The condensed consolidated statements of cash flows outline cash inflows and outflows from operating, investing, and financing activities for the six months ended June 30, 2025 and 2024 **NEXGEL, INC. Condensed Consolidated Statements of Cash Flows (in thousands USD):** | | Six Months Ended June 30, | | | :---------------------------------------------------------- | :------------ | :------------ | | | **2025** | **2024** | | Operating Activities | | | | Net loss | $(1,377) | $(1,738) | | Adjustments to reconcile net loss to net cash used in operating activities: | | | | Income (loss) attributable to non-controlling interest in joint venture | 59 | (146) | | Depreciation and amortization | 225 | 144 | | Net changes in operating lease assets and liabilities | 21 | 22 | | Share-based compensation and restricted stock vesting | 293 | 118 | | Gain on investment in marketable securities | — | (57) | | Changes in fair value of warrant liability and warrant modification expense | (104) | (26) | | Changes in operating assets and liabilities: | | | | Accounts receivable, net | 180 | 28 | | Inventory | (70) | (127) | | Prepaid expenses and other assets | (240) | (68) | | Accounts payable | 65 | 117 | | Accounts payable – related party | (84) | (105) | | Accrued expenses and other current liabilities | 224 | (113) | | Deferred revenue | 1 | 159 | | **Net Cash Used in Operating Activities** | **(807)** | **(1,792)** | | Investing Activities | | | | Proceeds from sales of marketable securities | — | 57 | | Capital expenditures | (20) | (361) | | Net cash paid for asset acquisition | — | (400) | | **Net Cash Used in Investing Activities** | **(20)** | **(704)** | | Financing Activities | | | | Proceeds from equity offering, net of expenses | — | 946 | | Investment by joint venture partner | — | 37 | | Payment of contingent consideration liability | (178) | (69) | | Principal payment on financing lease liability | (29) | (22) | | Principal payments of notes payable | (48) | (27) | | **Net Cash Provided by (Used in) Financing Activities** | **(255)** | **865** | | **Net Decrease in Cash** | **(1,082)** | **(1,631)** | | Cash – Beginning of period | 1,807 | 2,700 | | **Cash – End of period** | **$725** | **$1,069** | | Supplemental Disclosure of Cash Flows Information | | | | Cash paid during the year for: | | | | Interest | $18 | $27 | | Taxes | $— | $— | | Supplemental Non-cash Investing and Financing activities | | | | Shares issued in conjunction with asset acquisition | $— | $200 | | Property and equipment financed under notes payable | $— | $165 | | Property and equipment financed under financing leases | $— | $416 | Reconciliation of Non-GAAP Measures [Calculation of EBITDA & Adjusted EBITDA](index=7&type=section&id=Calculation%20of%20EBITDA%20%26%20Adjusted%20EBITDA) This section provides a detailed reconciliation of GAAP net loss to the non-GAAP measures of EBITDA and Adjusted EBITDA for the respective periods **Reconciliation of GAAP Measures to Non-GAAP Measures (in thousands USD):** | | Three Months Ended | | | Six Months Ended June 30, | | | :------------------------------------------ | :------------ | :------------ | :------------ | :------------ | :------------ | | | **March 31, 2025** | **June 30, 2025** | **June 30, 2024** | **2025** | **2024** | | Net (loss) income: | $(678) | $(640) | $(979) | $(1,318) | $(1,884) | | Less: Loss (income) attributable to non-controlling interest in joint venture | (34) | (25) | 94 | (59) | 146 | | **Net loss attributable to NexGel stockholders** | **(712)** | **(665)** | **(885)** | **(1,377)** | **(1,738)** | | Adjustments: | | | | | | | Depreciation and amortization | 114 | 111 | 92 | 225 | 144 | | Interest expense, net | 21 | 21 | 29 | 42 | 44 | | Income tax expense | - | - | - | - | - | | **EBITDA** | **(577)** | **(533)** | **(764)** | **(1,110)** | **(1,550)** | | Change in warrant liability(1) | (91) | (13) | (79) | (104) | (26) | | Share-based compensation expense(2) | 166 | 127 | 55 | 293 | 118 | | **Adjusted EBITDA:** | **$(502)** | **$(419)** | **$(788)** | **$(921)** | **$(1,458)** | - Adjustments for EBITDA include depreciation and amortization, interest expense, and income tax expense[25](index=25&type=chunk) - Further adjustments for Adjusted EBITDA include the non-cash change in warrant liability and share-based compensation expense[25](index=25&type=chunk)[26](index=26&type=chunk)

Financial Performance - Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% compared to $1.44 million for the same period in 2024 [1][4] - Gross profit for the quarter was $1.26 million, with a gross profit margin of 43.6%, compared to a gross profit of $0.29 million and a margin of 20.3% for the same period in 2024 [6][8] - The net loss attributable to NEXGEL stockholders was $0.67 million, an improvement from a net loss of $0.89 million in Q2 2024 [9][8] Business Growth and Strategy - The year-over-year revenue growth was driven by increased consumer demand for branded products and new agreements in contract manufacturing [3] - The company expects significant growth opportunities in the second half of 2025 due to new consumer product launches and onboarding new contract manufacturing customers [3] - A partnership with STADA was expanded, including a $1 million advance in non-dilutive capital to support product launches and marketing efforts [10][3] Cost and Expenses - Cost of revenues for the second quarter of 2025 was $1.63 million, up from $1.15 million in Q2 2024, primarily due to sales growth in branded consumer products [5] - Selling, general and administrative expenses totaled $1.89 million for the second quarter of 2025, compared to $1.27 million for the same period in 2024, driven by increases in compensation, advertising, and professional fees [7] Future Outlook - The company is reiterating its revenue guidance for 2025 of $13 million and aims to achieve positive EBITDA during the year [1][3] - As of June 30, 2025, the company had a cash balance of approximately $0.73 million, with additional financing of $1.05 million secured to support growth initiatives [10]

Company Overview - NEXGEL creates custom hydrogel solutions and develops patented medical devices, custom/white label products, and OTC healthcare consumer products[7] - The company has agreements with multi-billion dollar corporations[9] - NEXGEL has one of two state-of-the-art manufacturing facilities in North America that can produce hydrogel transdermal products[14] - The facility has a total capacity of over 1.4 billion square inches of product per year[15] Strategic Partnerships - Cintas Corporation will distribute NEXGEL's SilverSeal wound care solution to its customers[41] - STADA Arzneimittel AG is partnering with NEXGEL to expand its OTC product portfolio, with their first joint product, Histasolv, generating over $20 million in annualized European revenue[42] - CG Converting and Packaging is the exclusive supplier of gel pads for AbbVie's Rapid Acoustic Pulse device, with AbbVie acquiring Soliton for $550 million in December 2021[43] Financial Performance - Q2 2025 revenue was $2.88 million, a 100% increase compared to $1.44 million for Q2 2024[50] - Q2 2025 gross profit was $1.26 million with a profit margin of 43.6%, compared to 20.3% in Q2 2024[50] - The company reiterates revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year[50] Acquisitions - Silly George Beauty Brand was acquired in May 2024 and has an annual run-rate of over $5 million[36] - Kenkoderm Skincare Line was acquired in December 2023 and is immediately accretive[40]

Core Viewpoint - NEXGEL, Inc. is set to report its financial results for the second quarter of 2025 on August 12, 2025, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - The financial results for the second quarter of 2025 will be released after market close on August 12, 2025 [1]. - A conference call will be held at 4:30 P.M. ET on the same day to discuss the financial results [2]. Group 2: Company Overview - NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications [3]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [3]. - NEXGEL's product brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George, and it has strategic contract manufacturing relationships with major consumer healthcare companies [3].

As the CAO of Shutterstock, a leading global creative platform offering high-quality digital content, Mr. Ciardiello leads a global finance team responsible for SEC reporting, tax, internal audit, and general accounting. Since joining Shutterstock in 2016, he has led numerous financial transformation initiatives, improved reporting efficiency, and led efforts to streamline enterprise resource planning and financial operations. Prior to Shutterstock, Mr. Ciardiello held several finance leadership positions o ...

Core Viewpoint - NEXGEL, Inc. has announced a definitive agreement for the issuance and sale of 413,044 shares of common stock at $2.30 per share, along with unregistered warrants for an additional 206,522 shares at an exercise price of $4.25, aimed at strengthening its balance sheet and providing working capital for anticipated growth in the second half of the year [1][2]. Group 1: Financial Details - The total number of shares being offered is 413,044 at a price of $2.30 each [1]. - Concurrently, NEXGEL will issue unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25, which are immediately exercisable for five years [1][2]. - The financing, combined with a recent $1 million non-dilutive advance from STADA, enhances the company's cash position [2]. Group 2: Regulatory Information - The shares are being offered under the company's shelf registration statement on Form S-3, which was declared effective by the SEC on June 7, 2023 [3]. - The unregistered warrants are offered under an exemption from registration requirements of the Securities Act [4]. Group 3: Company Overview - NEXGEL is a provider of healthcare, beauty, and OTC products, specializing in ultra-gentle, high-water-content hydrogels [6]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [6].

Company Overview - NEXGEL, Inc. is a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, based in Langhorne, Pennsylvania [1][3] - The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades and offers brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George [3] Partnership Expansion - NEXGEL announced an expansion of its partnership with STADA Arzneimittel AG, a European leader in consumer health, which includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks [1][2] - As part of the agreement, STADA will provide $1 million in non-dilutive capital to support NEXGEL's product launches and marketing efforts [2] Financial Performance of STADA - In the financial year 2024, STADA achieved group sales of €4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation, and amortization (adj. cc EBITDA) of €886 million [2] - STADA operates globally, selling products in over 100 countries and employing 11,649 people as of December 31, 2024 [2]

Company Overview - NEXGEL, Inc. is a leading provider of healthcare, beauty, and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogels [3] - The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades [3] - NEXGEL's product brands include SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George [3] - The company has established strategic contract manufacturing relationships with leading consumer healthcare companies [3] Event Participation - Adam Levy, the Chief Executive Officer of NEXGEL, will participate in the 6th Annual CEO Networking Event hosted by Semco Capital in Chicago on June 2, 2025 [1] - The event will feature a fireside chat with Scott Weis of Semco Capital [1] - The Annual CEO Networking Event aims to bring together leading microcap companies with unique business models and strong management teams [2]